False Biomarker Discovery Due to Reactivity of a Commercial ELISA for CUZD1 with Cancer Antigen CA125
Clinical Chemistry Podcast · Association for Diagnostics and Laboratory Medicine
October 4, 201312m 6s
Show Notes
The discovery phase of proteomics is critical in the identification of suitable markers for exploration and validation of promising new clinical tests. But can laboratories be certain if what they believe they are measuring is, in fact, what they actually measuring?